Posted in | News | Semiconductor | Business

New Collaboration to Develop Low Cost Interposer Technology for 2.5D Ics

Singapore’s A*STAR Institute of Microelectronics (IME), Qualcomm Technologies Inc., a wholly owned subsidiary of Qualcomm Incorporated, and STATS ChipPAC have announced a collaboration to develop technology building blocks for Low Cost Interposers (LCI) for 2.5D ICs.

"2.5D/3D IC technology provides ample opportunities to further increase functionality and performance of semiconductor ICs. A collaborative approach is necessary for the industry to harness 2.5D/3D IC technologies successfully,” said Prof. Dim-Lee Kwong, Executive Director of IME. “IME’s consortium with Qualcomm Technologies and STATS ChipPAC focuses on pushing forward cost-effective manufacturing approaches in a timely manner.”

"This initiative extends our R&D efforts in the 2.5D/3D technologies and is another example of our investment in the silicon technology space,” said Jim Lederer, executive vice president and general manager, Qualcomm Technologies. “The collaboration with IME and STATS ChipPAC will help us support the ability to optimize 2.5D/3D IC technology and achieve cost and performance needs.”

“We are pleased to be part of this consortium to develop 2.5D technology solutions to address issues related to high volume manufacturing of 2.5D interposers,” said Dr. Han Byung Joon, Executive Vice President and Chief Technology Officer, STATS ChipPAC. “This collaboration, in conjunction with STATS ChipPAC’s proven expertise in manufacturing 2.5D/3D ICs, expands our strategic relationship with Qualcomm Technologies and IME.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.